Health

STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 22/10/2026, 20:21:24 UTC.

Briefings

A clinical trial by Moderna and Merck found a personalized mRNA cancer vaccine reduced melanoma recurrence risk by 42% versus standard care. Patients lived significantly longer without cancer returning. The vaccine targets unique tumor mutations called neoantigens using mRNA technology previously used for Covid-19 vaccines.

Key points

• A personalized mRNA cancer vaccine reduced the risk of disease recurrence in melanoma patients by 42% compared to standard treatment.
• Patients lived significantly longer without their cancer returning in the trial.

Context

The trial involved patients with melanoma treated with the Moderna-Merck vaccine, which attacks unique tumor mutations called neoantigens. This approach leverages mRNA technology previously used for Covid-19 vaccines.

Limitations

Evidence is limited to the specific melanoma trial conducted by Moderna and Merck. The study does not provide data on broader applicability across different cancer types or other treatment comparisons.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 22/10/2026, 21:05:29 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiatdtfsmmlooiur6jpmmrncmahwmc4pdtxbaqgxehwuxdx635x2e4